Xeris Biopharma (NASDAQ:XERS) Announces Earnings Results

Posted by Stanley Muller on Aug 8th, 2026

Xeris Biopharma (NASDAQ:XERS – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19), FiscalAI reports. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%. The company had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million.

Here are the key takeaways from Xeris Biopharma’s conference call:

Second-quarter revenue reached a record $92.1 million, with net product revenue up 34% year over year to $91 million; adjusted EBITDA increased more than 50% to $19.3 million.
RECORLEV revenue surged 81% to $56.8 million, supported by record referrals, new patient starts, and prescriber growth. Management expects the expanded commercial team to contribute further in the second half.
Xeris raised and narrowed full-year 2026 revenue guidance to $385 million-$390 million, citing sustained portfolio momentum and an expected rebound in Gvoke, while KEVEYIS received a patent allowance that could extend protection through at least 2039.
The company fully retired its $34 million of convertible debt in July, eliminating approximately $3 million in annual interest expense and simplifying the balance sheet, although the transaction generated a one-time, non-cash GAAP charge of about $31 million in the second quarter.
Xeris plans to increase full-year SG&A by approximately $50 million and R&D by $25 million versus 2025, primarily to support RECORLEV expansion and the planned year-end Phase III start for XP-8121; management expects R&D spending to rise further as the trial ramps in 2027.

Xeris Biopharma Price Performance

Xeris Biopharma stock opened at $7.93 on Friday. Xeris Biopharma has a 52-week low of $5.25 and a 52-week high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The firm’s fifty day moving average is $7.68 and its 200 day moving average is $6.80. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -72.09 and a beta of 0.66.

Insiders Place Their Bets

In other news, insider Kevin Mcculloch sold 90,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total value of $722,700.00. Following the sale, the insider directly owned 1,691,126 shares in the company, valued at $13,579,741.78. The trade was a 5.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the transaction, the director directly owned 126,500 shares of the company’s stock, valued at approximately $770,385. The trade was a 11.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 266,499 shares of company stock worth $1,996,417. Insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

Several large investors have recently modified their holdings of the stock. Corient Private Wealth LLC purchased a new position in shares of Xeris Biopharma during the fourth quarter valued at approximately $84,000. Jain Global LLC purchased a new position in Xeris Biopharma in the 4th quarter worth about $87,000. Mercer Global Advisors Inc. ADV purchased a new position in Xeris Biopharma in the 3rd quarter worth about $85,000. Tower Research Capital LLC TRC lifted its holdings in Xeris Biopharma by 913.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company’s stock valued at $81,000 after buying an additional 15,678 shares in the last quarter. Finally, Modern Wealth Management LLC bought a new stake in Xeris Biopharma during the 2nd quarter valued at about $83,000. Institutional investors own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

XERS has been the subject of a number of research analyst reports. Weiss Ratings upgraded Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

View Our Latest Analysis on Xeris Biopharma

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.